Drug Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage Clinical Trial

Official title:

Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage: the Feasibility of Drug Therapy and Its Impact on Cerebral Blood Flow

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04940273
• Other study ID #: KY2021-001
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2021
• Est. completion date: March 31, 2022

Study information

• Verified date: June 2021
• Source: Capital Medical University
• Contact: Zhou Jian-Xin, MD
• Phone: 010-59976518
• Email: zhoujx.cn[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although spontaneous hyperventilation patients with aneurysmal subarachnoid hemorrhage closely associated with poor outcomes, the standard therapy remains unavailable. Remifentanil has the pharmacological characterization of respiratory inhibition, mainly prolonging the expiratory time and decreasing the respiratory rate while preserving the respiratory drive. The investigators hypothesis that spontaneous hyperventilation could be corrected by titrating the dose of remifentanil and cerebral blood flow will augment during this process.

Description:

Evidence has shown a high incidence of spontaneous hyperventilation in patients with aneurysmal subarachnoid hemorrhage (aSAH), which is associated with poor outcomes. It's well established that the hypocapnia caused by hyperventilation leads to cerebral vasoconstriction, reduces the cerebral blood flow, and decreases the cerebral blood volume and intracranial pressure consequently. However, persistent cerebral vascular constriction increases the risk of cerebral ischemia; therefore, maintaining a partial pressure of arterial carbon dioxide (PaCO2) in the range of 35-40mmHg is recommended to minimize the hazard hypocapnia.

There's still no standard method to deal with spontaneous hyperventilation. Based on the pharmacology and clinical experience, remifentanil seems to be an ideal choice since it could inhibit the respiratory rate in a dose-dependent fashion. As one of the most used short-acting opioids, remifentanil could prolong the expiratory time, meanwhile not influencing the inspiratory time and respiratory drive, consequently decreasing respiratory rate and maintaining the tidal volume.

In this exploratory physiology study, the investigators will test the hypothesis that spontaneous hyperventilation could be suppressed by titrating the dose of remifentanil and could be realized as the target of PaCO2. The investigators will determine the optimal amount of remifentanil, which fulfills the criteria of efficacy and safety, and evaluate its effect on the cerebral blood flow velocity of both the middle cerebral artery and internal carotid artery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aneurysmal subarachnoid hemorrhage, after craniotomy or clipping

• Arterial blood gas satisfy with PaCO2<35mmHg and pH>7.45

• Presence of an endotracheal tube

• Assisted ventilation mode,CPAP/PSV

• ICP monitoring

Exclusion Criteria:

• Age <18 years

• Pregnancy

• Chronic obstructive pulmonary disease

• Allergy to opioids

• Clinically relevant hepatic or renal failure

• Hemodynamic instability

• TCD windows cannot detect cerebral blood flow

• Refuse to participate the study

Related Conditions & MeSH terms

• Aneurysmal Subarachnoid Hemorrhage
• Cerebral Blood Flow
• Hemorrhage
• Hyperventilation
• Subarachnoid Hemorrhage

Intervention

Drug:
• Remifentanil Injection [Ultiva]
Continuous infusion of remifentanil at a dose of 0.02?0.04?0.06?0.08 ug/kg/min for 30 minutes in sequence.

Locations

Country	Name	City	State
China	ICU, Beijing Tiantan Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Explore the effective and safe dose of remifentanil to correct spontaneous hyperventilation in patients with aSAH	The differences of partial pressure of carbon dioxide (PaCO2; mmHg) between the respective points (baseline and 30 minutes following each infusion rate adjustment of remifentanil) were recorded to determine the change of PaCO2 (mmHg).	The PaCO2 (mmHg) at baseline and 30 minutes following each infusion rate adjustment (0.02?0.04?0.06?0.08µg/kg/min)
Secondary	To explore the effect of remifentanil on the cerebral blood flow in patients with aSAH at the different dose	The differences of mean cerebral flow velocity (MFV) of middle cerebral artery and Internal carotid artery between baseline and 30 minutes following each infusion rate adjustment of remifentanil were recorded to determine the change of cerebral blood flow.	The MFV at baseline and 30 minutes following each infusion rate adjustment (0.02?0.04?0.06?0.08µg/kg/min)